RE: Massive boost to Livebiotherapeutic microbiome sector10 Aug 2020 14:52
There’s always more PR wise but imo the issue has been Acacia selling. Singer did an excellent job placing the shares and then we got another seller (s).
The issue has been the double placing against unproven, new therapeutics which is risky.
It doesn’t matter how much you PR it, it’s new hence the Seres news derisks this a bit.
This is one where you really gotta DYOR. The directors experience and skin in here are my main reasons together with the faith from Merck. They let us play with Keytruda a blockbuster! $7bn in revs! You don’t show anyone that dna unless you have faith.
So hopefully you can see the upside but also the downside risks from the last few posts.
Duncan has done loads on proactive, directors talk etc but clever Mr Market wants more than promises and jam before it rerates us.
DYOR = being ahead of the curve from here just don’t know for sure which way it will turn! Lol!
My money is north!
ATB
Trek